Back to top
more

Thermo Fisher Scientific (TMO)

(Delayed Data from NYSE)

$460.72 USD

460.72
1,689,919

+5.98 (1.32%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $460.90 +0.18 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (145 out of 244)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Zacks Equity Research

Here's Why You Should Avoid Betting on Integer Holdings (ITGR)

by Zacks Equity Research

Stiff competition in the MedTech space and weak segmental and operational third-quarter 2020 performance weighs on Integer Holdings (ITGR).

Zacks Equity Research

QIAGEN (QGEN), BioNTech to Develop Test to Identify SCCHN

by Zacks Equity Research

QIAGEN (QGEN) aims to leverage its global reach and position in CDx and HPV testing by collaborating with BioNTech.

Zacks Equity Research

Zacks Industry Outlook Highlights: ResMed, Thermo Fisher Scientific, IDEXX Laboratories and STERIS

by Zacks Equity Research

Zacks Industry Outlook Highlights: ResMed, Thermo Fisher Scientific, IDEXX Laboratories and STERIS

Zacks Equity Research

Thermo Fisher's (TMO) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Thermo Fisher Scientific (TMO).

Zacks Equity Research

Allscripts' (MDRX) Veradigm Collaborates With HealthVerity

by Zacks Equity Research

Allscripts (MDRX) and HealthVerity will be committed toward catering to specific industry needs by helping clients design linked data solutions that are fit-for-purpose.

Zacks Equity Research

Hologic's (HOLX) Cervical Cancer Screening System Gets CE Mark

by Zacks Equity Research

Hologic (HOLX) becomes the provider of the first CE-Marked comprehensive cervical cancer screening portfolio with the new Genius Digital Diagnostics System.

Zacks Equity Research

Here's Why You Should Hold NextGen (NXGN) in Your Portfolio Now

by Zacks Equity Research

Investor optimism is high on NextGen (NXGN) stock, thanks to solid prospects.

Urmimala Biswas headshot

3 Best Buys from the Prospering Medical Instruments Industry

by Urmimala Biswas

Despite the challenges posed by the COVID-19 pandemic, higher demand for lab-testing products, digital influence, and AI and robotics is likely to lend support to the Zacks Medical - Instruments industry. TMO, IDXX and STE are well positioned to gain.

Zacks Equity Research

Here's Why You Should Hold on to QIAGEN (QGEN) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about QIAGEN (QGEN) on robust segmental and geographical growth.

Zacks Equity Research

Medtronic's (MDT) Medicrea Buyout to Aid AI Spinal Surgery Line

by Zacks Equity Research

Medtronic (MDT) expects Medicrea's capabilities and solutions to complement its fully-integrated procedural solution for surgical planning and delivery.

Zacks Equity Research

QIAGEN (QGEN) Launches PCR Test, Expands Testing Portfolio

by Zacks Equity Research

QIAGEN (QGEN) aims to expand its NeuMoDx testing menu with the latest test launch and label extension.

Zacks Equity Research

Teleflex (TFX) Hurt by COVID-19-Led Disruption, UroLift Grows

by Zacks Equity Research

Teleflex (TFX) expects further adverse financial impact of the coronavirus pandemic.

Zacks Equity Research

AngioDynamics (ANGO) Shows Solid Results from RAPID Database

by Zacks Equity Research

The RAPID study proved that AngioDynamics' (ANGO) AngioVac System was versatile, safe and effective for the removal of vascular thrombi and cardiac masses.

Zacks Equity Research

Here's Why You Should Add Hologic (HOLX) to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Hologic (HOLX) on robust growth of the Diagnostics segment and regulatory approvals.

Zacks Equity Research

Hologic (HOLX) Updates Its Unifi Platform, Enhances Portfolio

by Zacks Equity Research

Hologic (HOLX) introduces upgrades to its Unifi Analytics platform to help mammography centers improve their workflow.

Zacks Equity Research

Ecolab Introduces Exelerate TUFSOIL for Food Manufacturers

by Zacks Equity Research

Ecolab's (ECL) Exelerate TUFSOIL has been developed to increase production time and enhance cleaning outcomes to curb food safety risks and improve worker safety.

Zacks Equity Research

Abbott (ABT) Launches Radiofrequency Ablation Device in U.S.

by Zacks Equity Research

Abbott (ABT) aims to expand its Neuromodulation portfolio with the latest launch of its radiofrequency ablation device.

Zacks Equity Research

Becton Dickinson (BDX) Buys Medical Business Assets of CUBEX

by Zacks Equity Research

This should further boost BD's (BDX) Medical segment.

Zacks Equity Research

Tivity Health's (TVTY) Shares Fall Despite Q3 Earnings Beat

by Zacks Equity Research

Tivity Health (TVTY) reports solid revenue growth in its Nutrition arm in the third quarter due to strength in Nutrisystem brand DTC.

Zacks Equity Research

HMS Holdings (HMSY) Climbs 7.4% Post In-Line Q3 Earnings

by Zacks Equity Research

HMS Holdings (HMSY) witnessed revenue growth in COB and PI segments in the third quarter.

Zacks Equity Research

Owens & Minor's (OMI) Shares Fall Despite Q3 Earnings Beat

by Zacks Equity Research

Owens & Minor (OMI) reports solid revenue growth in its Global Products arm in the third quarter due to strength in PPE sales.

Zacks Equity Research

AMN Healthcare (AMN) Loses 9.4% Despite Q3 Earnings Beat

by Zacks Equity Research

AMN Healthcare (AMN) gained from Technology and Workforce Solutions segment in the third quarter.

Zacks Equity Research

Glaukos (GKOS) Beats Estimates on Narrower-than-Expected Loss (revised)

by Zacks Equity Research

Glaukos' (GKOS) third-quarter results reflect a rise in revenues and recovery in the U.S. Glaucoma franchise.

Zacks Equity Research

Hill-Rom (HRC) Q4 Earnings, Revenues Top Estimates, Fall Y/Y

by Zacks Equity Research

In Q3, Hill-Rom's (HRC) bed orders and backlog in the United States accelerates with sequential recovery in Patient Support Systems arm.

Zacks Equity Research

Glaukos (GKOS) Gains 11.8% Despite Reporting Loss in Q3

by Zacks Equity Research

Glaukos' (GKOS) third-quarter results reflect rise in revenues and recovery in the U.S. Glaucoma franchise.